Why the study?
Does the presence of anti-p53 antibody correlate with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people with differing clinical status?
Does the presence of anti-p53 antibody correlate with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people with differing clinical status?
Anti-p53 antibody is not a useful serological marker for the clinical management of HTLV-I infected people, though Tof protein is immunogenic in vivo.
No takes yet. Share an insight, caveat, or question.
Anti-p53 antibody shows low prevalence without Tax correlation across HTLV-I states; should not yet alter serological monitoring and leaves open Tof immunogenicity questions.
Chen et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: